Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 18 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Medication-Related Osteonecrosis of the Jaw According to Antiresorptive Treatment Indication: Disease Severity and Associated Factors

  • Ivona Mihaela Hum1,2
  • Raluca Maracineanu1
  • Laura Atyim1,2
  • Daniela Gurgus2
  • Robert-Nikolas Folescu3
  • Loredana Gabriela Stana4
  • Roxana Folescu5
5 affiliations
  1. 1Doctoral School, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
  2. 2Department of Balneology, Medical Recovery and Rheumatology, Family Medicine University Clinic, Center for Preventive Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
  3. 3Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
  4. 4Department I, Discipline of Anatomy and Embryology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
  5. 5Department of Balneology, Medical Recovery and Rheumatology, Family Medicine University Clinic, Center for Preventive Medicine, Center for Advanced Research in Cardiovascular Pathology and Hemostaseology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Open at sourceDOICite

Abstract

Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) may differ in clinical presentation and severity according to the indication for antiresorptive therapy. This study compared patients with MRONJ treated for an oncologic indication or osteoporosis and evaluated factors associated with advanced disease, defined as American Association of Oral and Maxillofacial Surgeons (AAOMS) stages II and III. Methods: This retrospective observational study included 119 patients with MRONJ, comprising 73 patients with an oncologic indication and 46 treated for osteoporosis. Demographic, clinical, treatment-related, and selected biochemical data were collected from medical records. MRONJ severity was classified according to the AAOMS staging system. Between-group differences were assessed using non-parametric and categorical tests, and multivariable logistic regression was used to examine associations with advanced MRONJ after adjustment for selected covariates. Results: Patients with an oncologic indication were younger and had a shorter duration of antiresorptive therapy than those treated for osteoporosis. The distribution of AAOMS stages differed between groups (p = 0.001). Stage III disease was more frequent in the oncologic group than in the osteoporosis group (32.9% vs. 8.7%), whereas stage II frequencies were similar (43.8% vs. 41.3%). Advanced MRONJ was also more frequent in the oncologic group (76.7% vs. 50.0%; p = 0.003). In the multivariable model, older age (OR, 1.16; 95% CI, 1.06–1.27; p = 0.001) and diabetes mellitus (OR, 8.88; 95% CI, 2.29–34.50; p = 0.002) were associated with higher odds of advanced MRONJ. Compared with oncologic patients, those treated for osteoporosis had lower adjusted odds of advanced disease (OR, 0.14; 95% CI, 0.05–0.44; p < 0.001). No statistically significant association between recorded treatment duration and advanced MRONJ was detected in the sensitivity analysis. Conclusions: MRONJ severity differed between patients treated for an oncologic indication and those treated for osteoporosis, with the difference particularly pronounced for stage III disease. These findings should be interpreted in the context of differences in antiresorptive treatment regimens and do not establish an independent causal effect of treatment indication.

Related

  1. Biphasic remodeling and trabecular-cortical uncoupling in the jawbone during antiresorptive therapy and medication-related osteonecrosis: A quantitative imaging analysis.
    Ling-Ying Wei, Jun-Ching Lee, Ching-Ming Chiu +6
    Journal of dental sciencesPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Early-onset medication-related osteonecrosis of the jaw in adolescents with Duchenne muscular dystrophy receiving long-term antiresorptive combined with glucocorticoid therapy: Two case reports
    Agathe Rio, Patricia Olivier, Coralie Leblicq +2
    Bone reportsPeer-reviewedCC BY-NCFull textOncologyEurope PMCEurope PMCPMC
  3. Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw
    Ana Karina Sarmiento Liévano, Hannah Vanessa Ceballos Sarmiento, Nicolás Jiménez Vega +2
    Osteoporosis InternationalPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  4. Effect of guideline-assisted prompting on large language model performance in medication-related osteonecrosis of the jaw–related endodontic decision-making
    Mehmet Ali Altunkum, Gizem Akın Tartuk, Tolga Mavigöz +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref
  5. Medication‐Related Osteonecrosis of the Jaw After Dental Extractions During High‐Dose Denosumab Therapy in a Patient With Paget's Disease: A Case Report
    Toktam Zamani, Pegah Mosannen Mozaffari, Kazem Anvari +5
    Clinical Case ReportsPeer-reviewedCC BY 4.0Full textOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{hum2026medicationrelated,
  title = {{Medication-Related Osteonecrosis of the Jaw According to Antiresorptive Treatment Indication: Disease Severity and Associated Factors}},
  author = {Ivona Mihaela Hum and Raluca Maracineanu and Laura Atyim and Daniela Gurgus and Robert-Nikolas Folescu and Loredana Gabriela Stana and Roxana Folescu},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218402},
  url = {https://www.mdpi.com/2077-0383/15/21/8402},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Medication-Related Osteonecrosis of the Jaw According to Antiresorptive Treatment Indication: Disease Severity and Associated Factors
AU  - Ivona Mihaela Hum
AU  - Raluca Maracineanu
AU  - Laura Atyim
AU  - Daniela Gurgus
AU  - Robert-Nikolas Folescu
AU  - Loredana Gabriela Stana
AU  - Roxana Folescu
PY  - 2026
DA  - 2026/10/28
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218402
UR  - https://www.mdpi.com/2077-0383/15/21/8402
AB  - Background/Objectives: Medication-related osteonecrosis of the jaw (MRONJ) may differ in clinical presentation and severity according to the indication for antiresorptive therapy. This study compared patients with MRONJ treated for an oncologic indication or osteoporosis and evaluated factors associated with advanced disease, defined as American Association of Oral and Maxillofacial Surgeons (AAOMS) stages II and III. Methods: This retrospective observational study included 119 patients with MRONJ, comprising 73 patients with an oncologic indication and 46 treated for osteoporosis. Demographic, clinical, treatment-related, and selected biochemical data were collected from medical records. MRONJ severity was classified according to the AAOMS staging system. Between-group differences were assessed using non-parametric and categorical tests, and multivariable logistic regression was used to examine associations with advanced MRONJ after adjustment for selected covariates. Results: Patients with an oncologic indication were younger and had a shorter duration of antiresorptive therapy than those treated for osteoporosis. The distribution of AAOMS stages differed between groups (p = 0.001). Stage III disease was more frequent in the oncologic group than in the osteoporosis group (32.9% vs. 8.7%), whereas stage II frequencies were similar (43.8% vs. 41.3%). Advanced MRONJ was also more frequent in the oncologic group (76.7% vs. 50.0%; p = 0.003). In the multivariable model, older age (OR, 1.16; 95% CI, 1.06–1.27; p = 0.001) and diabetes mellitus (OR, 8.88; 95% CI, 2.29–34.50; p = 0.002) were associated with higher odds of advanced MRONJ. Compared with oncologic patients, those treated for osteoporosis had lower adjusted odds of advanced disease (OR, 0.14; 95% CI, 0.05–0.44; p < 0.001). No statistically significant association between recorded treatment duration and advanced MRONJ was detected in the sensitivity analysis. Conclusions: MRONJ severity differed between patients treated for an oncologic indication and those treated for osteoporosis, with the difference particularly pronounced for stage III disease. These findings should be interpreted in the context of differences in antiresorptive treatment regimens and do not establish an independent causal effect of treatment indication.
SN  - 2077-0383
ER  -